These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 15482145)

  • 1. Advances in the management of Chlamydia pneumoniae infections.
    Hammerschlag MR
    Expert Rev Anti Infect Ther; 2003 Oct; 1(3):493-503. PubMed ID: 15482145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chlamydophila pneumoniae.
    Blasi F; Tarsia P; Aliberti S
    Clin Microbiol Infect; 2009 Jan; 15(1):29-35. PubMed ID: 19220337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Choice of antimicrobial drug for infections caused by Chlamydia trachomatis and Chlamydophila pneumoniae].
    Zele-Starcević L; Plecko V; Budimir A; Kalenić S
    Acta Med Croatica; 2004; 58(4):329-33. PubMed ID: 15700690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Chlamydial infections: 2014 update.
    Kohlhoff SA; Hammerschlag MR
    Expert Opin Pharmacother; 2015 Feb; 16(2):205-12. PubMed ID: 25579069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging role of Mycoplasma pneumoniae and Chlamydia pneumoniae in paediatric respiratory-tract infections.
    Principi N; Esposito S
    Lancet Infect Dis; 2001 Dec; 1(5):334-44. PubMed ID: 11871806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eradication of Chlamydia pneumoniae from coronary artery endothelium.
    Hammerschlag MR
    Cardiovasc Drugs Ther; 2002 Mar; 16(2):167; author reply 169. PubMed ID: 12090910
    [No Abstract]   [Full Text] [Related]  

  • 7. Infection-mediated asthma: etiology, mechanisms and treatment options, with focus on Chlamydia pneumoniae and macrolides.
    Webley WC; Hahn DL
    Respir Res; 2017 May; 18(1):98. PubMed ID: 28526018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of CEM-101, a new fluoroketolide antibiotic, against Chlamydia trachomatis and Chlamydia (Chlamydophila) pneumoniae.
    Roblin PM; Kohlhoff SA; Parker C; Hammerschlag MR
    Antimicrob Agents Chemother; 2010 Mar; 54(3):1358-9. PubMed ID: 20038627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of garenoxacin against recent clinical isolates of Chlamydia pneumoniae.
    Roblin PM; Reznik T; Hammerschlag MR
    Int J Antimicrob Agents; 2003 Jun; 21(6):578-80. PubMed ID: 12791473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outbreak and persistence of Chlamydia pneumoniae infection in an Italian family.
    Migliorini L; Canocchi V; Zanelli G; Valassina M; Cellesi C
    Infez Med; 2003 Sep; 11(3):157-60. PubMed ID: 14985649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chlamydia pneumoniae as a respiratory pathogen.
    Hahn DL; Azenabor AA; Beatty WL; Byrne GI
    Front Biosci; 2002 Mar; 7():e66-76. PubMed ID: 11861211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does respiratory infection due to Chlamydia pneumoniae still exist?
    Senn L; Jaton K; Fitting JW; Greub G
    Clin Infect Dis; 2011 Oct; 53(8):847-8. PubMed ID: 21921229
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of Chlamydia pneumoniae.
    Hammerschlag MR
    Int J Antimicrob Agents; 2000 Aug; 15(3):239, 241. PubMed ID: 10926449
    [No Abstract]   [Full Text] [Related]  

  • 14. Mycoplasma pneumoniae and Chlamydia pneumoniae cause lower respiratory tract disease in paediatric patients.
    Principi N; Esposito S
    Curr Opin Infect Dis; 2002 Jun; 15(3):295-300. PubMed ID: 12015465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High prevalence of Chlamydia pneumoniae infection in cyclosporin A-induced post-transplant gingival overgrowth tissue and evidence for the possibility of persistent infection despite short-term treatment with azithromycin.
    Worm HC; Wirnsberger GH; Mauric A; Holzer H
    Nephrol Dial Transplant; 2004 Jul; 19(7):1890-4. PubMed ID: 15128877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chlamydia pneumoniae and the lung.
    Hammerschlag MR
    Eur Respir J; 2000 Nov; 16(5):1001-7. PubMed ID: 11153568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro susceptibility and eradication of Chlamydia pneumoniae cardiovascular strains from coronary artery endothelium and smooth muscle cells.
    Gieffers J; Solbach W; Maass M
    Cardiovasc Drugs Ther; 2001; 15(3):259-62. PubMed ID: 11713894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pneumonia due to Chlamydia pneumoniae in children: epidemiology, diagnosis, and treatment.
    Hammerschlag MR
    Pediatr Pulmonol; 2003 Nov; 36(5):384-90. PubMed ID: 14520720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chlamydia pneumoniae and Mycoplasma pneumoniae.
    Blasi F; Tarsia P; Aliberti S; Cosentini R; Allegra L
    Semin Respir Crit Care Med; 2005 Dec; 26(6):617-24. PubMed ID: 16388430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of telithromycin, a new ketolide, against Chlamydia pneumoniae.
    Miyashita N; Fukano H; Niki Y; Matsushima T
    J Antimicrob Chemother; 2001 Sep; 48(3):403-5. PubMed ID: 11533006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.